UBS Group
KURA icon

UBS Group’s Kura Oncology KURA Stock Holding History

UBS Group’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Sell
964,636
-75,597
-7% -$713K ﹤0.01% 3378
2026
Q1 		$8.46M Sell
1,040,233
-19,792
-2% -$170K ﹤0.01% 3531
2025
Q4 		$11M Buy
1,060,025
+574,455
+118% +$6.03M ﹤0.01% 3187
2025
Q3 		$4.3M Buy
485,570
+373,287
+332% +$2.66M ﹤0.01% 4193
2025
Q2 		$648K Sell
112,283
-27,242
-20% -$167K ﹤0.01% 5799
2025
Q1 		$921K Sell
139,525
-175,950
-56% -$1.37M ﹤0.01% 5347
2024
Q4 		$2.75M Buy
315,475
+185,659
+143% +$2.67M ﹤0.01% 4414
2024
Q3 		$2.54M Buy
129,816
+38,039
+41% +$771K ﹤0.01% 3759
2024
Q2 		$1.89M Sell
91,777
-135,044
-60% -$2.78M ﹤0.01% 3825
2024
Q1 		$4.84M Buy
226,821
+23,864
+12% +$464K ﹤0.01% 3008
2023
Q4 		$2.92M Buy
202,957
+120,612
+146% +$1.19M ﹤0.01% 3406
2023
Q3 		$751K Buy
82,345
+82,328
+484,282% +$836K ﹤0.01% 4340
2023
Q2 		$180 Sell
17
-214,123
-100% -$2.53M ﹤0.01% 8423
2023
Q1 		$2.62M Sell
214,140
-796
-0.4% -$9.93K ﹤0.01% 3148
2022
Q4 		$2.67M Buy
214,936
+181,705
+547% +$2.64M ﹤0.01% 3101
2022
Q3 		$454K Sell
33,231
-28,017
-46% -$432K ﹤0.01% 4420
2022
Q2 		$1.12M Sell
61,248
-127,571
-68% -$1.84M ﹤0.01% 3637
2022
Q1 		$3.04M Buy
188,819
+24,012
+15% +$347K ﹤0.01% 3047
2021
Q4 		$2.31M Buy
164,807
+153,363
+1,340% +$2.48M ﹤0.01% 3601
2021
Q3 		$214K Sell
11,444
-2,159
-16% -$40.7K ﹤0.01% 5264
2021
Q2 		$284K Sell
13,603
-44,396
-77% -$1.1M ﹤0.01% 5118
2021
Q1 		$1.64M Buy
57,999
+51,012
+730% +$1.61M ﹤0.01% 3768
2020
Q4 		$228K Buy
6,987
+1,353
+24% +$47.5K ﹤0.01% 5160
2020
Q3 		$173K Buy
5,634
+5,385
+2,163% +$119K ﹤0.01% 4875
2020
Q2 		$4K Sell
249
-16,301
-98% -$235K ﹤0.01% 7459
2020
Q1 		$165K Sell
16,550
-14,619
-47% -$167K ﹤0.01% 4874
2019
Q4 		$429K Sell
31,169
-47,500
-60% -$704K ﹤0.01% 4973
2019
Q3 		$1.19M Buy
78,669
+76,917
+4,390% +$1.37M ﹤0.01% 3809
2019
Q2 		$35K Buy
+1,752
New +$29.1K ﹤0.01% 6211
2019
Q1 		– Sell
-50,275
Closed -$705K – 7949
2018
Q4 		$705K Buy
50,275
+43,281
+619% +$573K ﹤0.01% 3994
2018
Q3 		$122K Buy
+6,994
New +$134K ﹤0.01% 5419
2018
Q2 		– Sell
-30,671
Closed -$575K – 8124
2018
Q1 		$575K Buy
30,671
+18,171
+145% +$354K ﹤0.01% 4117
2017
Q4 		$191K Sell
12,500
-2,704
-18% -$39.8K ﹤0.01% 4932
2017
Q3 		$227K Buy
+15,204
New +$143K ﹤0.01% 4760
2017
Q2 		– Sell
-2,639
Closed -$23K – 7834
2017
Q1 		$23K Buy
2,639
+872
+49% +$6.39K ﹤0.01% 6038
2016
Q4 		$10K Sell
1,767
-1,864
-51% -$9.99K ﹤0.01% 6922
2016
Q3 		$23K Buy
+3,631
New +$18.4K ﹤0.01% 6190
2016
Q2 		– Sell
-1,184
Closed -$5K – 7858
2016
Q1 		$5K Buy
+1,184
New +$5.62K ﹤0.01% 7007

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

UBS Group's KURA Position: Q2 2026 in Review

UBS Group reduced its Kura Oncology (KURA) stake by 7.3% in Q2 2026, selling an estimated $713K and leaving 964,636 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3378.

UBS Group first reported a position in KURA in Q1 2016 and has held it in 38 quarters since. The position peaked at $11M in Q4 2025. 220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • UBS Group held 964,636 shares of Kura Oncology worth $10.6M as of Q2 2026.
  • UBS Group sold 75,597 Kura Oncology shares in Q2 2026, an estimated $713K.
  • Kura Oncology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3378 holding.
  • UBS Group first reported a position in Kura Oncology in Q1 2016 and has held it in 38 quarters since.
  • UBS Group's Kura Oncology position peaked at $11M in Q4 2025.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.